AOD-9604 Reconstitution Calculator

No. AOD-9604 is an unapproved peptide sold direct to patients through the "gray market" without regulatory oversight. It progressed through phase II obesity trials with reported favourable safety and tolerability, but never completed approval for any indication. Gray-market product composition and dose accuracy are unverified. AOD-9604 is WADA-prohibited; screening methods detect the parent peptide in urine and a stable serum metabolite (fragment CRSVEGSCG),. The peptide has been identified in confiscated vials in the USA.

AOD-9604 is the C-terminal fragment of human growth hormone: hGH amino acids 177-191 with an added N-terminal tyrosine; it is commonly labelled the hGH 176-191 fragment. It reproduces GH's lipolytic (fat-releasing) action without receptor signalling: in vitro it does not compete for the hGH receptor and does not drive cell proliferation. In obese mice, 14 days of treatment reduced body-weight gain, increased fat oxidation, and raised plasma glycerol (a lipolysis marker). Obese Zucker rats given 500 µg/kg/day orally for 19 days gained >50% less weight with increased adipose lipolytic activity and no loss of insulin sensitivity on euglycemic clamp. (animal, mechanistic)

Human efficacy is unproven. Only early-phase development data exist, and reviews place AOD-9604 among GH-IGF1-axis peptides without a published human efficacy randomized controlled trial, leaving performance and recomposition claims uncertain. Perceived benefit is further confounded by placebo effects amplified through social media. Animal efficacy is consistent: increased fat oxidation and reduced weight gain in ob/ob mice, weight gain halved with oral dosing in Zucker rats. In a collagenase-induced knee osteoarthritis rabbit model, 0.25 mg intra-articular AOD9604 weekly reduced cartilage degeneration scores, and combining it with hyaluronic acid outperformed either alone. (human: phase II only; efficacy: animal)

No human route-comparison data exist. Oral efficacy is demonstrated only in rats (500 µg/kg/day). Community practice is predominantly subcutaneous injection for systemic fat-loss use, with 250-300 µg/day as the standard pattern (community protocol). Intra-articular injection has animal support for joint pathology; this route is occasionally used off-label for joints (community protocol). Injectable is the expected format for AOD-9604.

Human dose-finding data are absent; figures come from animal models and community practice.

The rodent oral benchmark does not translate directly to human subcutaneous dosing; most users standardize at 250–300 mcg once daily, flat (not weight-scaled) (community protocol). Storage: AOD-9604 degrades substantially in biological fluids within one week at 4-22 °C but remains stable frozen (-20 °C) for ≥2 months; treat reconstituted vials as perishable and keep refrigerated (community protocol).

No human maximum-duration data exist. Chronic animal exposures are short: 14 days in mice and 19 days in rats, without reported metabolic harm. Community fat-loss cycles run 8-12 weeks, with off-periods between cycles as standard practice (community protocol). Long-term human safety remains unknown; rigorous human safety data are scarce.

Both hGH and AOD-9604 reduced weight gain, increased fat oxidation, and stimulated lipolysis in obese mice. However, AOD-9604 did not induce hyperglycaemia or suppress insulin, and it does not bind the GH receptor. In rats, chronic AOD-9604 preserved insulin sensitivity, unlike intact hGH. This underpins its design claim as GH's lipolytic activity "without the diabetogenic side effects". No human head-to-head data exist; unlike hGH (an approved drug), AOD-9604 holds no approved indication. (animal, mechanistic)

No. There are no pregnancy or lactation studies, and gray-market product composition, dose, and sterility are unverified,. Growth-hormone-axis modulation carries unquantified endocrine risk. For people with dysglycaemia or diabetes: animal data showing preserved insulin sensitivity, are not a substitute for human glycaemic safety data, which do not exist. Any off-label use in special populations lacks an evidence basis.